Faculty introduction, disclosures

Introductory content: defining the context and challenge of FOP Epidemiology Clinical features, presentation, genetic testing, and pathophysiology Difficulties of diagnosis

Current therapy for FOP Patient management ·  Prevention of flare-ups ·  Avoid biopsies, surgery, and trauma ·  Immunizations ·  Glucocorticoid prophylaxis Symptomatic management of lesions ·  Glucocorticoids ·  NSAIDs/COX-2 inhibitors ·  Bisphosphonates ·  Mast cell inhibitors Preventative health maintenance: dental care, hearing evaluation, and respiratory health Transitioning from pediatric to adult care  Challenges to successful FOP treatment and strategies for addressing them  Emerging and future therapies · Retinoic acid receptor gamma agonism · Activin inhibition · Others Patient case(s)

Best practice recap

By the end of the session the participant will be able to:

• Recall the clinical presentation and diagnostic principles of FOP.
• Describe approaches for the successful transition from pediatric to adult care.
• Summarize challenges to the optimal diagnosis and treatment of FOP and strategies for overcoming them.
• Identify the current and emerging pharmacotherapeutic treatment options for the management of FOP.
• Formulate a treatment plan for a patient with FOP.

ACCME Activity #202440376

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved through content review by ScientiaCME.

Disclosure of Faculty: Patricia L.R. Delai, MD, Consultant Doctor for the Brazilian FOP Association, Hospital Israelita Albert Einstein, has received financial compensation as a principal investigator from Ipsen. 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Ipsen Biopharmaceuticals.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version